These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37421190)

  • 61. Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer.
    Suarez-Almazor ME; Ruiz JI; Lei X; Wu CF; Zhao H; Rajan SS; Giordano SH
    Clin Rheumatol; 2024 Nov; 43(11):3301-3312. PubMed ID: 39230743
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study.
    Lee SK; Shin K; Jung JY; Suh CH; Kim JW; Kim HA
    BioDrugs; 2023 Mar; 37(2):247-257. PubMed ID: 36757601
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology.
    Carrara G; Bortoluzzi A; Sakellariou G; Silvagni E; Zanetti A; Govoni M; Scirè CA
    Clin Exp Rheumatol; 2019; 37(1):60-66. PubMed ID: 30148440
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
    Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
    Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
    Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
    Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany.
    Krause D; Krause C; Rudolf H; Baraliakos X; Braun J; Schmitz E
    Clin Rheumatol; 2021 Mar; 40(3):887-893. PubMed ID: 32822057
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study.
    Radner H; Yoshida K; Hmamouchi I; Dougados M; Smolen JS; Solomon DH
    J Rheumatol; 2015 Jul; 42(7):1099-104. PubMed ID: 26034147
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study.
    Naffaa ME; Hassan F; Golan-Cohen A; Merzon E; Green I; Saab A; Paz Z
    Rheumatol Int; 2021 Nov; 41(11):1905-1913. PubMed ID: 34529109
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
    J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
    Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
    Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effectiveness and safety of original and biosimilar etanercept (Enbrel® vs Benepali®) in bDMARD-naïve patients in a real-world cohort of Portugal.
    Pinto AS; Cunha MM; Pinheiro F; Bernardes M; Assunção H; Martins-Martinho J; Tenazinha C; Monteiro AM; Silva S; Martins FR; Silva L; Couto M; Faria M; Araújo F; Fontes T; Santos-Faria D; Tavares-Costa J
    ARP Rheumatol; 2022; 1(2):109-116. PubMed ID: 35810368
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis.
    Das P; Weisenfeld D; Dahal K; De D; Feathers V; Coblyn JS; Weinblatt ME; Shadick NA; Cai T; Liao KP
    Arthritis Res Ther; 2023 Jun; 25(1):93. PubMed ID: 37269020
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics.
    Kawasumi H; Gono T; Tanaka E; Kaneko H; Kawaguchi Y; Yamanaka H
    J Rheumatol; 2016 Apr; 43(4):738-44. PubMed ID: 26834212
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.
    Richter A; Listing J; Schneider M; Klopsch T; Kapelle A; Kaufmann J; Zink A; Strangfeld A
    Ann Rheum Dis; 2016 Sep; 75(9):1667-73. PubMed ID: 26567181
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
    Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
    Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs.
    Valor L; Garrido J; Martínez-Estupiñán L; Hernández-Flórez D; Janta I; López-Longo FJ; Monteagudo I; González CM; Naredo E
    Rheumatol Int; 2018 Aug; 38(8):1465-1470. PubMed ID: 29915991
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.